Given that clinical trials focusing on targeting CD73 in GBM have yet to commence or are ongoing in other malignances, there is limited awareness of its associated adverse events beyond results from animal studies (Jin et al., 2021). The gene discussed is NT5E; the disease is glioblastoma.